Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — FY2025 Earnings Presentation
15 slides from Little Green Pharma's earnings presentation, Jun 11, 2025
Slide 1: FY2025 Annual Report presentation
FY2025 For personal use only Annual Report ASX:LGP presentation June 2025 The most trusted medicinal cannabis brand
Slide 2: Disclaimer
Disclaimer Disclaimer Not financial product advice For personal use only This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its This document does not constitute financial product advice or take into account your investment objectives, taxation
Slide 3: About LGP
ABOUT LGP Little Green Pharma For personal use only 30t 5 BRANDS 31 PRODUCTS 4 FACILITIES PRODUCTION CAPACITY 11 13 SPONSORED 94 STAFF ACROSS 20+ STRAINS DISTRIBUTION TERRITORIES STUDIES / TRIALS 5 COUNTRIES GENETICS BANK
Slide 4: Highlights for FY2025
FY2025 HIGHLIGHTS Highlights for FY2025 For personal use only • Revenue CAGR: 52% over FY2022–FY2025 with record revenue of $36.8 million in FY2025, up 43% on FY2024 • Adjusted EBITDA: $2.9 million (up from negative $1.6m in FY2024) • Net profit after tax (NPAT): $3.3 million (vs FY2024 loss of $8.2
Slide 5: Revenue: Strong revenue growth
REVENUE Strong revenue Revenue (A$m) growth For personal use only $45 Millions 36.8m $40 • CAGR of 52% over FY2022–FY2025 $35 with record revenue of $36.8 million in $30 25.8m FY2025, up 43% on FY2024 $25 19.9m • Health House: Gross distributor sales $20 $0.8m since acquisition, net revenue $15 10.5
Slide 6: Revenue (cont.): Diversified revenue base
REVENUE (CONT.) Revenue by product category (A$m)1,2 Diversified 10.9m revenue base For personal use only 8.7m 10.4m 23.2m 6.8m 15.8m 9.2m • Excellent revenue diversification across a 3.5m range of formulations and brands FY22 FY23 FY24 FY25 Flower Products Oil Products Vaporiser Products Other Reve
Slide 7: Adjusted EBITDA: Record adjusted EBITDA
ADJUSTED EBITDA Adjusted EBITDA1 (A$m) Record adjusted $5 2.9 Millions EBITDA $- FY22 FY23 FY24 FY25 For personal use only (1.6) -$5 • Record Adjusted EBITDA of $2.9 million, up from (5.9) negative $1.6 million in FY2024 -$10 • Adjustment factors: $2.4 million share-based -$15 payments, $3.7 million
Slide 8: NPAT: Profit
NPAT Profit Profit/(loss) after income tax (A$m) For personal use only • Company achieved a Net Profit After Tax of $3.3 $5 3.3 Millions million, up from a $8.2 million loss in FY2024 $- • Profit result supported by strong revenue growth FY22 FY23 FY24 FY25 FY25 (up 43%) and operational leverage, wi
Slide 9: NTA, EV, Cash & Debt
NTA, EV, CASH & DEBT NTA per share Strong NTA, $0.30 $0.25 $0.24 NTA per share Enterprise Value, For personal use only Share Price (A$) $0.20 cash & debt $0.15 $0.10 $0.05 • Net Tangible Assets: $73.0 million - Feb24 May24 Aug24 Nov24 Feb25 May25 • Enterprise Value = $39 million • Ratio EV: Revenue=
Slide 10: Global production assets
PRODUCTION ASSETS Global production assets For personal use only Denmark: largest production facility in Europe 2 hours from German border, with new 2tpa room commissioned during year and poised to take advance of expanded Danish cannabis cultivation and import rules* Western Australia: Subcontracte
Slide 11: Global footprint
PRODUCTION ASSETS Global footprint 10 Sweden For personal use only 5 Denmark • LGP has supplied or has supply arrangements for medicinal cannabis products into 11 countries 3 UK UK 2 Germany 8 Poland • LGP has grown its supply footprint since 2019, 7 Belgium beginning in Australia and progressing th
Slide 12: Corporate & Reset update
CORPORATE UPDATE Corporate & Reset update For personal use only Cannabiz Awards • Winner of 2025 Cannabiz Awards – "Best Place to Work" • Recognition of LGP's strong culture, high retention and staff engagement Board changes • Mr Paul Long and Mr David Fenlon were appointed to the board and Ms Beatr
Slide 13: Corporate overview
Corporate overview CORPORATE OVERVIEW Capital Structure (AUD) LGP Performance Since IPO Share Price 1/06/2025 $ 0.11 Volume Price Share Price ($) Volume (millions) For personal use only 52-Wk High/Low $ 0.17 / 0.08 $2.00 10.0 1. LGP Wins French government tender 2. Major customer DEMECAN locks in $2
Slide 14: Value proposition
VALUE PROPOSITION Value proposition For personal use only • 50% revenue CAGR between FY2022 and FY2025 and current Enterprise Value at 0.9x revenue • Significant low-debt asset base with NTA almost double Company’s current market valuation • Positioned in rapid growth markets (Australia, Germany and
Slide 15: Thank you
For personal use only Thank you